Xylem and Amazon Partner on Smart Water Upgrades to Save More Than 1.3 Billion Liters Annually in Mexico
11.9.2025 16:00:00 CEST | Business Wire | Press Release
Residents in Mexico City and Monterrey will soon enjoy more reliable water supply as the two cities launch groundbreaking infrastructure upgrades to save over 1.3 billion liters of water a year – easing pressure from the rapid urbanization and persistent drought conditions that have strained local water systems.
The two cities are working in partnership with global water technology company Xylem (NYSE: XYL) and Amazon (NASDAQ: AMZN) to deploy Xylem Vue, an advanced software platform that applies data and analytics to detect leaks, cut water losses and improve residents’ water supply. The projects are estimated to save upwards of 800 million liters of water a year in Mexico City and 560 million liters a year in Monterrey.
“In a water-stressed region, where every liter counts, recovering more than a billion liters of water each year is a game-changer,” said Jaime Barba, General Manager, Xylem Vue. “Working with Amazon and the local water utilities, we are using data to give these cities actionable insights that enable them to make their community’s water supply more resilient and secure.”
In Mexico City, where 9 million people rely on the municipal water system, up to 40% of water can be lost from leaky pipes before it ever reaches the tap. To address this issue, the new technology manages pressure in real time, reducing leakage and adapting to demand without stressing the pipes, and proactively locating leaks, making it easier to fix them faster.
By applying these solutions in partnership with Amazon and Xylem, Mexico City and Monterrey’s utilities are making infrastructure investments go further, helping secure more affordable and reliable water for their communities. A recent report from Xylem and Global Water Intelligence found that smart water systems can reduce the cost of urban drought resilience by as much as 20%.1
“This landmark investment from Amazon and advanced technology from Xylem address one of our city's most pressing challenges,” said Ricardo Alberto Munguía Alfaro, Deputy Secretary of Hydraulic Infrastructure Operations and Efficiency, SEGIAGUA (Mexico City’s Secretariat of Comprehensive Water Management). “This partnership demonstrates how public-private collaboration and innovation can create meaningful impact in urban water management. Together, we are building a more sustainable and water-resilient future for Mexico City.”
In Monterrey, the project expands an already successful deployment of Xylem Vue to two new districts, including one serving low-income residents who are especially vulnerable to supply disruptions. Monterrey will also use advanced leak detection, enabling faster response and repair to water loss.
“This innovative water conservation project arrives at a crucial time for our city," said Eduardo Ortegon Williamson, Deputy Director, Servicios de Agua y Drenaje de Monterrey. "The technology-driven approach to reducing water loss demonstrates how public-private partnerships can create immediate impact for residents, particularly in vulnerable communities most affected by water scarcity."
The partnership with Xylem is part of Amazon’s broader water stewardship efforts. The new water projects are part of more than 30 water replenishment projects Amazon has announced globally which, once completed, are expected to return more than 14 billion liters of water each year.
By working together, the two companies are showing how AI infrastructure can grow responsibly while also improving water security.
"We recognize that addressing water scarcity requires collaborative action on a global scale," said Rubén Mugártegui, AWS Mexico Managing Director. "Our investment demonstrates our commitment beyond maintaining facilities – we're working hand-in-hand with local municipalities and organizations to create sustainable solutions for the communities we serve."
About Xylem
Xylem (XYL) is a Fortune 500 leading global water solutions company that empowers customers and communities to build a more water-secure world. Our 23,000 diverse employees delivered revenue of $8.6 billion in 2024, optimizing water and resource management with innovation and expertise. Join us at www.xylem.com and let’s solve water.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250911628782/en/
Contacts
Media
Houston Spencer
+1 (914) 240-3046
Houston.Spencer@xylem.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom